tetano
Editor, Senior Moderator
Oncotarget. 2017 Dec 22;9(5):6623-6629. doi: 10.18632/oncotarget.23601. eCollection 2018 Jan 19.
[h=1]Forty five percent of the Israeli population were infected with the influenza B Victoria virus during the winter season 2015-16.[/h] Sharabi S[SUP]1,[/SUP][SUP]2[/SUP], Bassal R[SUP]3[/SUP], Friedman N[SUP]1,[/SUP][SUP]2[/SUP], Drori Y[SUP]1,[/SUP][SUP]2[/SUP], Alter H[SUP]1[/SUP], Glatman-Freedman A[SUP]2,[/SUP][SUP]3,[/SUP][SUP]4[/SUP], Hindiyeh M[SUP]1,[/SUP][SUP]2[/SUP], Cohen D[SUP]2[/SUP], Mendelson E[SUP]1,[/SUP][SUP]2[/SUP], Shohat T[SUP]2,[/SUP][SUP]3[/SUP], Mandelboim M[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] While infection with influenza A viruses has been extensively investigated, infections with influenza B viruses which are commonly categorized into the highly homologous Victoria and Yamagata lineages, are less studied, despite their considerable virulence. Here we used RT-PCR assays, hemagglutination inhibition assays and antibody titers to determine the levels of influenza B infection. We report of high influenza B Victoria virus prevalence in the 2015-16 winter season in Israel, affecting approximately half of the Israeli population. We further show that the Victoria B virus infected individuals of all ages and that it was present in the country throughout the entire winter season. The vaccine however included the inappropriate Yamagata virus. We propose that a quadrivalent vaccine, that includes both Yamagata and Victoria lineages, should be considered for future influenza vaccination.
[h=4]KEYWORDS:[/h] Victoria; Yamagata; influenza B; vaccine
PMID: 29464098 PMCID: PMC5814238 DOI: 10.18632/oncotarget.23601
Free PMC Article
[h=1]Forty five percent of the Israeli population were infected with the influenza B Victoria virus during the winter season 2015-16.[/h] Sharabi S[SUP]1,[/SUP][SUP]2[/SUP], Bassal R[SUP]3[/SUP], Friedman N[SUP]1,[/SUP][SUP]2[/SUP], Drori Y[SUP]1,[/SUP][SUP]2[/SUP], Alter H[SUP]1[/SUP], Glatman-Freedman A[SUP]2,[/SUP][SUP]3,[/SUP][SUP]4[/SUP], Hindiyeh M[SUP]1,[/SUP][SUP]2[/SUP], Cohen D[SUP]2[/SUP], Mendelson E[SUP]1,[/SUP][SUP]2[/SUP], Shohat T[SUP]2,[/SUP][SUP]3[/SUP], Mandelboim M[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] While infection with influenza A viruses has been extensively investigated, infections with influenza B viruses which are commonly categorized into the highly homologous Victoria and Yamagata lineages, are less studied, despite their considerable virulence. Here we used RT-PCR assays, hemagglutination inhibition assays and antibody titers to determine the levels of influenza B infection. We report of high influenza B Victoria virus prevalence in the 2015-16 winter season in Israel, affecting approximately half of the Israeli population. We further show that the Victoria B virus infected individuals of all ages and that it was present in the country throughout the entire winter season. The vaccine however included the inappropriate Yamagata virus. We propose that a quadrivalent vaccine, that includes both Yamagata and Victoria lineages, should be considered for future influenza vaccination.
[h=4]KEYWORDS:[/h] Victoria; Yamagata; influenza B; vaccine
PMID: 29464098 PMCID: PMC5814238 DOI: 10.18632/oncotarget.23601
Free PMC Article